UNSPSC 51101658: Ferric cacodylate

This classification denotes an antihelminthic agent with the molecular formula 3C2H6AsO2.Fe, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZCT01NZ5HD, chemically known as arsinic acid, dimethyl-, iron(3+) salt but generally known as ferric cacodylate, which bears US NIH Compound Identifier 22273. Most nations schedule ferric cacodylate under HS 28444030 and SITC 52519. As of Q4 2014, FERRIC CACODYLATE remains the US FDA Preferred Term for this commodity.

Ferric cacodylate bears US NLM identifiers UMLS ID C0991824 and NCI Concept Code C81518. SMILES: C[As](=O)(C)[O-].C[As](=O)(C)[O-].C[As](=O)(C)[O-].[Fe+3].

UNSPSC 51101658 Ferric cacodylate is a Commodity code that nominally describes a specific chemical compound, but recent state and local opportunities tagged under this code show minimal alignment with ferric cacodylate itself; instead, they reflect procurement of pharmaceuticals, medical supplies, and health-related products across a broader scope. State and local issuers soliciting under this code include county health departments, state health and human services agencies, and municipal fire rescue divisions. The work spans naloxone and drug deactivation systems for public health initiatives, generic pharmaceuticals and over-the-counter products distributed through state cooperative purchasing networks, medical and first aid supplies for emergency response, and pharmacy benefit program development.

Recent activity appears concentrated in Florida and across Midwestern and Western states participating in cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The City of Tampa issued IFB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000.00, with a sheltered-market set-aside for certified Small Local Business Enterprises and a 5 percent SLBE bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota, Oregon, and participating jurisdictions, with proposals due March 26, 2026, and awards effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer pharmacy benefit program capabilities, with a response deadline of April 3, 2026.